Clinicopathological Profiles and Prognosis of Postoperative HER2-Mutant Non-Small Cell Lung Cancer: A Real-World Analysis.
Her2-mutant NSCLC constitutes a distinct subtype characterized by unique clinicopathological and molecular features and for postoperative patients presenting with advanced disease or an increased burden of high-risk recurrence factors, more aggressive therapeutic strategies should be considered.